Aquilo Capital Management
Latest statistics and disclosures from Aquilo Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are XBI, Uniqure Nv shs, Dicerna Pharmaceuticals, Anaptysbio Inc Common, Xenon Pharmaceuticals, and represent 62.88% of Aquilo Capital Management's stock portfolio.
- Added to shares of these 10 stocks: Anaptysbio Inc Common (+$20.33M), Ngm Biopharmaceuticals Inc (+$12.91M), Arrowhead Pharmaceuticals (+$12.56M), Dicerna Pharmaceuticals (+$11.44M), Spero Therapeutics Inc (+$5.36M), Uniqure Nv shs, Xenon Pharmaceuticals, Proqr Thrapeutics N V shs euro, Morphosys Ag Adr, Pieris Pharmaceuticals.
- Started 3 new stock positions in Anaptysbio Inc Common, Ngm Biopharmaceuticals Inc, Arrowhead Pharmaceuticals.
- Reduced shares in these 4 stocks: XBI (-$19.36M), Galapagos Nv-spon (-$5.43M), Merus N V, Fate Therapeutics.
- Sold out of its positions in Fate Therapeutics.
- Aquilo Capital Management was a net buyer of stock by $48.29M.
- Aquilo Capital Management has $256.58M in assets under management (AUM), dropping by -3.63%.
Portfolio Holdings for Aquilo Capital Management
Companies in the Aquilo Capital Management portfolio as of the March 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Share Count | Change in Shares | Price |
|---|---|---|---|---|
| SPDR S&P; Biotech (XBI) | 30.18 | 1.00M | -20% | 77.44 |
| Uniqure Nv shs | 9.28 | 501975 | +26% | 47.45 |
| Dicerna Pharmaceuticals | 8.86 | 1.24M | +101% | 18.37 |
| Anaptysbio Inc Common | 7.92 | 1.44M | NEW | 14.13 |
| Xenon Pharmaceuticals | 6.63 | 1.50M | +28% | 11.34 |
| Spero Therapeutics Inc | 5.73 | 1.82M | +57% | 8.08 |
| Proqr Thrapeutics N V shs euro | 5.14 | 2.40M | +24% | 5.49 |
| Ngm Biopharmaceuticals Inc | 5.03 | 1.05M | NEW | 12.33 |
| Pieris Pharmaceuticals | 4.95 | 5.58M | +12% | 2.28 |
| Arrowhead Pharmaceuticals | 4.89 | 436514 | NEW | 28.77 |
| Merus N V | 3.63 | 770183 | -25% | 12.10 |
| Regenxbio Inc equity us cm | 3.45 | 273211 | 32.38 | |
| Galapagos Nv-spon | 3.38 | 44234 | -38% | 195.91 |
| Morphosys Ag Adr | 0.92 | 95898 | +1477% | 24.57 |
Download CSV 
Past Filings by Aquilo Capital Management
View past SEC 13F filings by Aquilo Capital Management
- Aquilo Capital Management 2019 Q4 filed Feb. 14, 2020
- Aquilo Capital Management 2019 Q3 filed Nov. 14, 2019
- Aquilo Capital Management 2019 Q2 filed Aug. 14, 2019
- Aquilo Capital Management 2019 Q1 filed May 15, 2019
- Aquilo Capital Management 2018 Q4 filed Feb. 14, 2019